Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 19, 2026, 5:25 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 313–336 of 5,448 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Control Subjects Clear all
Completed Phase 1 Interventional Accepts healthy volunteers

A SAD/MAD Study to Evaluate the Safety, Tolerability, PK and PD of MT2004

NCT04277910
View directory record Official record
Conditions
Healthy
Interventions
MT2004, Placebo
Drug
Lead sponsor
Xi'an Biocare Pharma Ltd.
Other
Eligibility
18 Years to 55 Years
Enrollment
88 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Apr 5, 2022 · Synced Oct 19, 2026, 5:25 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Investigate the Safety, Tolerability and Pharmacokinetics of GSK2336805 Alone and With the Co-administration of TMC435 in Healthy Japanese Participants.

NCT02018536
View directory record Official record
Conditions
Healthy
Interventions
GSK2336805 30 mg, GSK2336805 60 mg, GSK2336805 120 mg, TMC435 150 mg (Treatment A), GSK2336805 60 mg (Treatment B and part of Treatment C and D), TMC435 100 mg (part of Treatment C), TMC435 150 mg (part of treatment D)
Drug
Lead sponsor
Janssen R&D Ireland
Industry
Eligibility
20 Years to 55 Years
Enrollment
48 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2014
U.S. locations
1
States / cities
Cypress, California
Source: ClinicalTrials.gov public record
Updated Jun 17, 2014 · Synced Oct 19, 2026, 5:25 PM EDT
Completed Phase 2 Interventional

Efficacy and Safety of EN3324 (Axomadol) in Subjects With Chronic Low Back Pain

NCT01043263
View directory record Official record
Conditions
Chronic Low Back Pain
Interventions
EN3324 (axomadol), Placebo
Drug
Lead sponsor
Grünenthal GmbH
Industry
Eligibility
18 Years and older
Enrollment
236 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
59
States / cities
Phoenix, Arizona • Tucson, Arizona • Tuscon, Arizona + 43 more
Source: ClinicalTrials.gov public record
Updated Apr 2, 2015 · Synced Oct 19, 2026, 5:25 PM EDT
Terminated Phase 2 Interventional Results available

DUR-928 in Subjects With SARS-CoV-2 With Acute Lung, Liver or Kidney Injury

NCT04447404
View directory record Official record
Conditions
SARS-CoV-2
Interventions
DUR-928, Placebo
Drug
Lead sponsor
Durect
Industry
Eligibility
18 Years to 80 Years
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
Newark, New Jersey
Source: ClinicalTrials.gov public record
Updated Aug 5, 2022 · Synced Oct 19, 2026, 5:25 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Single Oral Dose Study Of PF-06427878 In Healthy Adult Subjects

NCT02208284
View directory record Official record
Conditions
Healthy
Interventions
PF-06427878, Placebo
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 55 Years
Enrollment
16 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Mar 4, 2015 · Synced Oct 19, 2026, 5:25 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

AZD9742 Single and Multiple Ascending Dose Study in Healthy Male and Female Japanese Subjects

NCT01114152
View directory record Official record
Conditions
Healthy
Interventions
AZD9742, Placebo
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
23 Years to 45 Years
Enrollment
35 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010
U.S. locations
1
States / cities
Glendale, California
Source: ClinicalTrials.gov public record
Updated Aug 3, 2010 · Synced Oct 19, 2026, 5:25 PM EDT
Not listed Phase 1 Interventional Accepts healthy volunteers

Single Ascending Dose Study Investigating the Safety, Tolerability, and PK of XC130-A10H in Healthy Adult Subjects

NCT04043338
View directory record Official record
Conditions
Parkinson's Disease
Interventions
XC130-A10H, Placebo
Drug
Lead sponsor
Xoc Pharmaceuticals
Industry
Eligibility
18 Years to 75 Years
Enrollment
56 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2022
U.S. locations
1
States / cities
Tempe, Arizona
Source: ClinicalTrials.gov public record
Updated Sep 23, 2021 · Synced Oct 19, 2026, 5:25 PM EDT
Completed Phase 2 Interventional Results available

Albiglutide Glucose Clamp Study in Subjects With Type 2 Diabetes

NCT01475734
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
albiglutide, placebo
Biological
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 60 Years
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
1
States / cities
Chula Vista, California
Source: ClinicalTrials.gov public record
Updated Jan 11, 2017 · Synced Oct 19, 2026, 5:25 PM EDT
Completed Phase 2 Interventional Results available

Phase 2a Study of HPG1860 in Subjects With NASH

NCT05338034
View directory record Official record
Conditions
NASH - Nonalcoholic Steatohepatitis
Interventions
HPG1860, Placebo
Drug
Lead sponsor
Hepagene (Shanghai) Co., Ltd.
Industry
Eligibility
18 Years to 75 Years
Enrollment
89 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
Texas City, Texas
Source: ClinicalTrials.gov public record
Updated May 28, 2026 · Synced Oct 19, 2026, 5:25 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Safety, Tolerability, and Immunogenicity of CRV-101 in Healthy Adult Subjects

NCT03820414
View directory record Official record
Conditions
Herpes Zoster, Varicella Zoster
Interventions
CRV 101, Placebo
Biological
Lead sponsor
Curevo Inc
Industry
Eligibility
18 Years to 49 Years
Enrollment
90 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2020
U.S. locations
1
States / cities
Kansas City, Missouri
Source: ClinicalTrials.gov public record
Updated Feb 11, 2021 · Synced Oct 19, 2026, 5:25 PM EDT
Terminated Phase 1 Interventional Results available

A Study to Evaluate the Safety, Tolerability, and Blood Levels of PF-03654746 in Subjects With Mild to Moderate Alzheimer's Disease

NCT01028911
View directory record Official record
Conditions
Alzheimer's Disease
Interventions
PF-03654746, Placebo
Drug
Lead sponsor
Pfizer
Industry
Eligibility
55 Years to 85 Years
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
2
States / cities
Wichita, Kansas
Source: ClinicalTrials.gov public record
Updated Jun 4, 2014 · Synced Oct 19, 2026, 5:25 PM EDT
Completed Phase 2 Interventional

A Comparison of SLx-4090 in Combination With Metformin Versus Metformin Therapy Alone in Patients With Type 2 Diabetes

NCT00871936
View directory record Official record
Conditions
Type 2 Diabetes
Interventions
SLx-4090, Placebo, Metformin
Drug · Other
Lead sponsor
Response Pharmaceuticals
Industry
Eligibility
18 Years to 75 Years
Enrollment
82 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009
U.S. locations
12
States / cities
Anaheim, California • Burbank, California • Los Angeles, California + 8 more
Source: ClinicalTrials.gov public record
Updated Nov 18, 2023 · Synced Oct 19, 2026, 5:25 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A 2-Part Single Dose Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of E2006

NCT01463098
View directory record Official record
Conditions
Insomnia
Interventions
E2006 1.0 mg, E2006 2.5 mg, E2006 5.0 mg, E2006 10.0 mg, E2006 25.0 mg, E2006 50.0 mg, E2006 100 mg, E2006 200 mg, Zolpidem 10 mg, E2006 Matched Placebo or Zolpidem Matched Placebo, E2006 Matched Placebo
Drug
Lead sponsor
Eisai Inc.
Industry
Eligibility
18 Years to 64 Years
Enrollment
122 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2012
U.S. locations
2
States / cities
New York, New York • Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Jan 18, 2020 · Synced Oct 19, 2026, 5:25 PM EDT
Not listed Phase 2 Interventional

Study to Evaluate Safety and Efficacy of ALLO-ASC-SHEET in Subjects With Dystrophic Epidermolysis Bullosa

NCT05157958
View directory record Official record
Conditions
Dystrophic Epidermolysis Bullosa
Interventions
ALLO-ASC-SHEET, Vehicle Control
Biological · Other
Lead sponsor
Anterogen Co., Ltd.
Industry
Eligibility
4 Years to 60 Years
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Apr 22, 2024 · Synced Oct 19, 2026, 5:25 PM EDT
Not listed Phase 2 Interventional

Study of the Efficacy and Safety of AMT-101 in Subjects With Ulcerative Colitis (LOMBARD)

NCT04583358
View directory record Official record
Conditions
Ulcerative Colitis
Interventions
AMT-101 (oral), Placebo (oral)
Drug · Other
Lead sponsor
Applied Molecular Transport
Industry
Eligibility
18 Years to 80 Years
Enrollment
105 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
15
States / cities
Rialto, California • Orlando, Florida • Port Orange, Florida + 12 more
Source: ClinicalTrials.gov public record
Updated Nov 7, 2022 · Synced Oct 19, 2026, 5:25 PM EDT
Completed Phase 2Phase 3 Interventional Results available

A Phase 2b, Study of Linsitinib in Subjects With Active, Moderate to Severe Thyroid Eye Disease (TED)

NCT05276063
View directory record Official record
Conditions
Thyroid Eye Disease, Graves Orbitopathy, Endocrine System Diseases, Eye Diseases, Thyroid Associated Ophthalmopathy, Graves Ophthalmopathy, Thyroid Diseases, Orbital Diseases, Proptosis, IGF1R, Exophthalmos, Hashimoto
Interventions
Linsitinib, Placebo
Drug
Lead sponsor
Sling Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
19
States / cities
Beverly Hills, California • La Jolla, California • Los Angeles, California + 15 more
Source: ClinicalTrials.gov public record
Updated Sep 23, 2026 · Synced Oct 19, 2026, 5:25 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Assess Electrophysiology, Safety, Tolerability, and Pharmacokinetics of Multiple Doses of SAGE-718 Using Ketamine Challenge in Healthy Subjects

NCT03844906
View directory record Official record
Conditions
Healthy Volunteer
Interventions
SAGE-718, Placebo
Drug
Lead sponsor
Supernus Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2019
U.S. locations
2
States / cities
Long Beach, California • Berlin, New Jersey
Source: ClinicalTrials.gov public record
Updated Sep 17, 2025 · Synced Oct 19, 2026, 5:25 PM EDT
Terminated Phase 3 Interventional Results available

Study Assessing the Efficacy and Safety of Alpelisib + Nab-paclitaxel in Subjects With Advanced TNBC Who Carry Either a PIK3CA Mutation or Have PTEN Loss

NCT04251533
View directory record Official record
Conditions
Triple Negative Breast Neoplasms
Interventions
alpelisib, placebo, nab-paclitaxel
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 100 Years
Enrollment
137 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2026
U.S. locations
5
States / cities
Los Angeles, California • Baton Rouge, Louisiana • Rochester, Minnesota + 2 more
Source: ClinicalTrials.gov public record
Updated Sep 10, 2026 · Synced Oct 19, 2026, 5:25 PM EDT
Completed Phase 2 Interventional Results available

Study Evaluating Intepirdine (RVT-101) in Subjects With Dementia With Lewy Bodies: The HEADWAY-DLB Study

NCT02669433
View directory record Official record
Conditions
Dementia With Lewy Bodies
Interventions
RVT-101 35 mg, RVT-101 70 mg, Placebo
Drug
Lead sponsor
Axovant Sciences Ltd.
Industry
Eligibility
50 Years to 85 Years
Enrollment
484 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
31
States / cities
Phoenix, Arizona • Sun City, Arizona • Tucson, Arizona + 26 more
Source: ClinicalTrials.gov public record
Updated Apr 26, 2019 · Synced Oct 19, 2026, 5:25 PM EDT
Completed Phase 3 Interventional Results available

A Study of Safety and Efficacy of MK-1986 (Tedizolid Phosphate) and Comparator in Participants From Birth to Less Than 12 Years of Age With Acute Bacterial Skin and Skin Structure Infections (MK-1986-018)

NCT03176134
View directory record Official record
Conditions
Acute Bacterial Skin and Skin Structure Infections
Interventions
Tedizolid phosphate, Comparator
Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
1 Day to 11 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
8
States / cities
San Diego, California • Chicago, Illinois • Detroit, Michigan + 5 more
Source: ClinicalTrials.gov public record
Updated Jul 31, 2025 · Synced Oct 19, 2026, 5:25 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

TD-6450 SAD and MAD in Healthy Subjects

NCT02022306
View directory record Official record
Conditions
Hepatitis C
Interventions
TD-6450, Placebo
Drug
Lead sponsor
Theravance Biopharma
Industry
Eligibility
18 Years to 60 Years
Enrollment
111 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Jan 14, 2021 · Synced Oct 19, 2026, 5:25 PM EDT
Completed Phase 2 Interventional

Safety and Efficacy of Natalizumab in Combination With Remicade in the Treatment of Crohn's Disease

NCT00055536
View directory record Official record
Conditions
Crohn's Disease
Interventions
natalizumab
Drug
Lead sponsor
Biogen
Industry
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2003
U.S. locations
18
States / cities
Gainesville, Florida • Jacksonville, Florida • Atlanta, Georgia + 14 more
Source: ClinicalTrials.gov public record
Updated Jun 16, 2016 · Synced Oct 19, 2026, 5:25 PM EDT
Completed Not applicable Interventional Results available

Neomycin and Rifaximin Plus Neomycin in Treating Methane Positive Constipation Predominant Irritable Bowel Syndrome

NCT00945334
View directory record Official record
Conditions
Constipation-predominant Irritable Bowel Syndrome
Interventions
Neomycin, Placebo, Rifaximin
Drug
Lead sponsor
Mark Pimentel, MD
Other
Eligibility
18 Years to 75 Years
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
2
States / cities
Los Angeles, California • Augusta, Georgia
Source: ClinicalTrials.gov public record
Updated Aug 10, 2015 · Synced Oct 19, 2026, 5:25 PM EDT
Terminated Phase 2 Interventional

Placebo Controlled Study of VS-6063 in Subjects With Malignant Pleural Mesothelioma

NCT01870609
View directory record Official record
Conditions
Malignant Pleural Mesothelioma
Interventions
defactinib (VS-6063), Placebo
Drug
Lead sponsor
Verastem, Inc.
Industry
Eligibility
18 Years and older
Enrollment
344 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
12
States / cities
San Francisco, California • Weston, Florida • Chicago, Illinois + 9 more
Source: ClinicalTrials.gov public record
Updated Jan 30, 2017 · Synced Oct 19, 2026, 5:25 PM EDT